早期类风湿关节炎患者停用CZP后仍可观察到1年联合治疗的临床获益:C-OPERA研究2年结果
C-OPERA研究纳入具有不良预后因素的甲氨蝶呤(MTX)初治早期类风湿关节炎(RA)患者,随机接受优化MTX联合certolizumab pegol(CZP)或安慰剂治疗52周,随后单独使用MTX至104周。结果显示,联合CZP组在104周时影像学进展抑制率和缓解率均显著优于安慰剂组,停用CZP后仍维持获益,因复发再治疗者快速改善,不良事件发生率相似。
要点
- 早期RA不良预后患者初始联合CZP 1年,停用后2年影像学获益仍显著。
- 104周时CZP+MTX组SDAI和Boolean缓解率显著高于安慰剂+MTX组。
- 因复发再治疗者快速临床改善,整体不良事件发生率两组相似。
核心结论
- 在MTX初治的早期RA不良预后患者中,初始1年联合CZP治疗可带来持续2年的影像学和临床获益,即使停用CZP后仍可观察到。
研究设计与样本
- 多中心随机对照III期C-OPERA研究,包括52周双盲期和随后52周治疗后随访期。
- MTX初治早期RA不良预后患者随机接受优化MTX+CZP(n=159)或优化MTX+安慰剂(n=157)。
- 双盲期后患者进入随访期,仅接受MTX治疗(CZP+MTX→MTX组n=108,安慰剂+MTX→MTX组n=71),复发者可接受开放标签CZP救援治疗。
主要发现
- 第52周至第104周,CZP+MTX组较安慰剂+MTX组显著抑制改良总Sharp评分进展(第104周:84.2% vs 67.5%,p<0.001)。
- 停用CZP后缓解率下降,但CZP+MTX→MTX组至第104周仍维持较高缓解率:SDAI缓解41.5% vs 29.3%(p=0.026),Boolean缓解34.6% vs 24.2%(p=0.049),DAS28(ESR)缓解41.5% vs 33.1%(p=0.132)。
- 因复发接受CZP再治疗的患者(n=28)显示快速临床改善,两组总体不良事件发生率相似。
关键数值与推荐
- 第104周影像学进展抑制率:CZP+MTX组84.2%,安慰剂+MTX组67.5%(p<0.001)。
- 第104周SDAI缓解率:CZP+MTX→MTX组41.5%,安慰剂+MTX→MTX组29.3%(p=0.026)。
- 第104周Boolean缓解率:CZP+MTX→MTX组34.6%,安慰剂+MTX→MTX组24.2%(p=0.049)。
- 第104周DAS28(ESR)缓解率:CZP+MTX→MTX组41.5%,安慰剂+MTX→MTX组33.1%(p=0.132)。
临床怎么用
- 对于MTX初治的早期RA不良预后患者,可考虑初始1年联合CZP治疗以改善2年影像学和临床结局。
- 停用CZP后仍需密切监测疾病活动,复发者可及时再治疗并获得快速改善。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To investigate the clinical impact of 1-year certolizumab pegol (CZP) therapy added to the first year of 2-year methotrexate (MTX) therapy, compared with 2-year therapy with MTX alone. METHODS: MTX-naïve patients with early rheumatoid arthritis (RA) with poor prognostic factors were eligible to enter Certolizumab-Optimal Prevention of joint damage for Early RA (C-OPERA), a multicentre, randomised, controlled study, which consisted of a 52-week double-blind (DB) period and subsequent 52-week post treatment (PT) period. Patients were randomised to optimised MTX+CZP (n=159) or optimised MTX+placebo (PBO; n=157). Following the DB period, patients entered the PT period, receiving MTX alone (CZP+MTX→MTX; n=108, PBO+MTX→MTX; n=71). Patients who flared could receive rescue treatment with open-label CZP. RESULTS: 34 CZP+MTX→MTX patients and 14 PBO+MTX→MTX patients discontinued during the PT period. From week 52 through week 104, significant inhibition of total modified total Sharp score progression was observed for CZP+MTX versus PBO+MTX (week 104: 84.2% vs 67.5% (p<0.001)). Remission rates decreased after CZP discontinuation; however, higher rates were maintained through week 104 in CZP+MTX→MTX versus PBO+MTX→MTX (41.5% vs 29.3% (p=0.026), 34.6% vs 24.2% (p=0.049) and 41.5% vs 33.1% (p=0.132) at week 104 in SDAI, Boolean and DAS28(erythrocyte sedimentation rate) remission. CZP retreated patients due to flare (n=28) showed rapid clinical improvement. The incidence of overall adverse events was similar between groups. CONCLUSIONS: In MTX-naïve patients with early RA with poor prognostic factors, an initial 1 year of add-on CZP to 2-year optimised MTX therapy brings radiographic and clinical benefit through 2 years, even after stopping CZP. TRIAL REGISTRATION NUMBER: NCT01451203.
引用
- Atsumi T, Tanaka Y, Yamamoto K, et al. Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial. Ann Rheum Dis. 2017. PMID: 28153828. doi:10.1136/annrheumdis-2016-210246
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。